This month, the Secretary of the U.S. Department of Health and Human Services (HHS) – Robert F. Kennedy, Jr. – testified at seven congressional committee hearings, offering some good insight into where the Trump Administration intends to go on healthcare policy in the months ahead.
HHS appears to be clarifying its priorities, with an agenda centered on price transparency, program integrity, and structural reform across both public and private health insurance markets.
A central theme emerging from Kennedy’s appearances before House and Senate committees is skepticism toward the current structure of Patient Protection and Affordable Care Act (PPACA) marketplaces. In testimony before House lawmakers, he sharply criticized the methods that have contributed to lower premiums in recent years, arguing that tax subsidies and relaxed enrollment policies have created only the “illusion” of affordability, rather than addressing underlying healthcare costs. This framing suggests the Administration may be preparing to revisit how PPACA coverage is subsidized and regulated, potentially favoring policies that emphasize cost containment over expanded financial assistance.
Closely tied to this approach is the Administration’s renewed push for healthcare price transparency. Kennedy highlighted the need for stronger statutory provisions that would require Medicare and Medicaid plans to publicly disclose pricing in a more accessible and standardized way. By urging Congress to advance the president’s “Great Healthcare Plan,” HHS says it is placing transparency at the center of its agenda. The underlying idea is that clearer pricing information will increase competition and ultimately drive down costs, though the effectiveness of such measures remains a subject of debate among policymakers and industry stakeholders.
Another notable HHS priority is reform of preventive care regulation. Kennedy’s criticism of the U.S. Preventive Services Task Force – that’s the body that determines which preventive services insurers must cover – indicates ongoing dissatisfaction with the current pace and direction of the Task Force’s decision-making.
As a result, the Secretary initiated a call for nominations to replace the 16-member panel, and is clearly prepared to reshape how preventive care recommendations are developed. This move could have far-reaching implications, as the panel’s determinations directly influence insurance coverage requirements and patient access to preventive services.
Beyond regulatory and policy reforms, the Administration is also prioritizing program integrity, particularly within Medicaid. Under Kennedy’s direction, Centers for Medicare & Medicaid Services (CMS) Administrator Dr. Mehmet Oz announced last week a nationwide initiative to combat Medicaid fraud, requiring states to rapidly revalidate providers and submit detailed anti-fraud strategies. This effort is being reinforced by coordination with the U.S. Department of Justice (DOJ), which is intensifying enforcement actions in areas such as PPACA marketplace fraud.
Together, these measures reveal a broader emphasis on safeguarding federal healthcare spending and reducing fraud, waste, and abuse.
The convergence of these initiatives – PPACA marketplace scrutiny, transparency mandates, preventive care restructuring, and anti-fraud enforcement – exposes a fairly coherent policy direction. Rather than focusing primarily on expanding coverage, the Administration appears intent on tightening oversight, increasing accountability, and addressing system inefficiencies.
However, these priorities also raise some important questions. We’ve already seen that efforts to reduce PPACA subsidies and alter enrollment practices affect coverage levels.
Changes to the Preventive Services Task Force may introduce new debates over the role of evidence-based medicine versus political influence in determining preventive care standards. And while transparency and anti-fraud measures are broadly supported, their real-world impact still depends on implementation and enforcement.
Ultimately, Kennedy’s recent tour testifying before congressional committees offers a window into how the Administration wants to move forward on federal healthcare policy. So stay tuned, because we’ve learned where HHS’s focus lies – on transparency, integrity, affordability, and structural reform – which may result in some significant policy activity that influences how Americans access, pay for, and understand their healthcare.
References:
- [2026-04-22] Hearing: The President’s Fiscal Year 2027 Department of Health and Human Services Budget | The United States Senate Committee on Finance
- RFK Jr. vows to end ‘illusion’ of lower premiums under ACA
- HHS issues call for nominations to Preventive Services Task Force
- Oz unveils nationwide plan to tackle Medicaid fraud at POLITICO Summit – POLITICO
- Robert F. Kennedy Jr. hearings target 340B, Medicare Advantage – Modern Healthcare
